1. Introduction {#sec0001}
===============

In December 2019, a series of patients with pneumonia caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported from Wuhan, Hubei province in China [@bib0001]. Since then, Coronavirus Disease 2019 (COVID-19) has spread globally with more than 6.300.000 infections and, by date, more than 370.00 deaths worldwide. The typical symptoms of SARS-CoV-2 infection, such as fever, cough, sore throat, or dyspnea, are well recognized and have been widely described [@bib0002], [@bib0003], [@bib0004], [@bib0005], [@bib0006] while also organs beyond the respiratory tract may be affected [@bib0007],[@bib0008].

SARS-CoV-2 is a beta-coronavirus that is closely related to severe acute respiratory syndrome corona virus (SARS-CoV) [@bib0009]. Both viruses use the angiotensin-converting enzyme--related carboxypeptidase (ACE2) as receptor to gain entry into mammalian cells [@bib0010]. Previous studies found that ACE2 expression is related to the severity of acute respiratory distress syndrome (ARDS) caused by SARS-CoV infection, and mediates the production of cytokines in ARDS [@bib0011],[@bib0012]. Massive release of pro-inflammatory cytokines results in a cytokine storm (also termed cytokine release syndrome (CRS)) which is characterized by elevated C-reactive protein (CRP), interleukin 6 (IL-6), lactate dehydrogenase (LDH) and ferritin concentration that is accompanied by organ dysfunction (such as ARDS, progressive liver damage and liver failure). As such, the systemic release of pro-inflammatory cytokines seems to be a driver of disease progression in COVID-19 [@bib0013], [@bib0014], [@bib0015].

The impact of SARS-CoV-2 on liver disease is poorly understood [@bib0016],[@bib0017]. Several studies reported clinical features of liver injury in COVID-19 patients [@bib0003], [@bib0004], [@bib0005], [@bib0006],[@bib0018], [@bib0019], [@bib0020] with elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) in 14% to 53% of COVID-19 patients [@bib0003],[@bib0005],[@bib0006] which could be an indicator for severe pneumonia [@bib0021]. Similarly, delayed hospital admission after illness onset was associated with increased risk of liver injury in patients with COVID-19 [@bib0022]. Notably, hepatic infiltration of lymphocytes, centrilobular sinusoidal dilation and patchy necrosis could be observed in COVID-19 patients [@bib0023],[@bib0024], and SARS-CoV-2 might directly bind to ACE2-expressing cholangiocytes [@bib0025]. However, the origin of liver injury remains unresolved and could be related to systemic inflammation, SARS-CoV-2 infection or drug administration [@bib0026].

IL-6 is a potent cytokine with diverse functions during hepatic inflammation and regeneration [@bib0027]. IL-6 serves inflammatory (danger) signaling and (because of its half life) better indicates systemic inflammation when compared to other cytokines, such as Interleukin-1 beta (IL-1β) or TNF-alpha (TNF-α) [@bib0028]. The aim of this study was to explore a link between systemic inflammation and liver injury in COVID-19.

2. Methods {#sec0002}
==========

2.1. Patients {#sec0003}
-------------

The study was performed at the University Hospital of Innsbruck, Austria, the only referral hospital in Tyrol, Austria. From February 26^th^, 2020 to April 21^st^, 2020, 655 patients with suspected COVID-19 were evaluated. 96 patients were diagnosed with COVID-19 based on the World Health Organization interim guidance [@bib0029]. 81 patients were hospitalized without the need for intensive care, while 15 patients required intensive care treatment on admission day. None of the included individuals was admitted to an intensive care unit (ICU) 3 months prior to study inclusion. 8 of 96 patients showed evidence of hepatic steatosis by ultrasonography (6/8 diagnosed with metabolic associated liver disease [@bib0030]) 3 to 12 month prior to hospitalization. No other chronic liver disease (such as chronic viral hepatitis, alcoholic liver disease, immune-mediated liver disorders or hemochromatosis) were documented in any patient and all patients had normal liver enzymes documented in previous biochemical studies (8.9 months ± 6.1months prior to hospitalization) . None of the patients received any antibiotic or antiviral therapy in the past 3 months. Fever was defined as body temperature ≥ 37.3°C and dyspnea was defined by a respiratory rate ≥ 20 breaths/minute and resting finger oxygen saturation ≤ 93% [@bib0031]. Gastrointestinal symptoms were recorded based on medical history taken at hospital admission. Diarrhea was defined by loose stools \> 3 times per day, vomiting was defined by ≥ 1 per day. All reported parameters were collected on admission day.

2.2. SARS-CoV2- analysis {#sec0004}
------------------------

Laboratory confirmation of SARS-CoV-2 infection was performed using previously described real-time polymerase chain reaction [@bib0004] as recommended by the Centers for Disease Control and Prevention (DeKalb, GA).

2.3. Liver parameters {#sec0005}
---------------------

Elevated liver tests were defined by the AST ≥ 50 Units/liter (U/l), ALT ≥ 50 U/l, gamma-glutamyl transferase (GGT) ≥ 71 U/l, alkaline phosphatase (AP) ≥ 129 U/l and total bilirubin ≥ 1.28 U/l assessed on admission day. In COVID-19 consensus on liver injury classification by biochemical means is lacking. Therefore, patients displaying AST concentrations (≥ 50 U/l) was considered to be increased (as in other clinical situations).

2.4. IL-6 and acute phase proteins {#sec0006}
----------------------------------

IL-6, CRP, LDH and ferritin were determined by Cobas 8000, (Roche, Basel, Switzerland) according to the manufacturer´s specification. The lower detection limit of the assay for IL-6 is \< 5 nanograms/mililter (ng/ml), for CRP 0,05 miligrams/deciliter (mg/dl) and 20 micrograms/liter (µg/l) for ferritin. The established cut-off value for CRP is 0,50 mg/dl, for LDH 100 U/l and for ferritin 400 µg/l.

2.5. Creatininkinase (CK), Troponin T and creatinine (Crea) {#sec0007}
-----------------------------------------------------------

CK, Troponin T and Crea were determined by Cobas 8000, (Roche, Basel, Switzerland) according to the manufacturer´s specification. The lower detection limit of the assay for CK is \< 10U/l, for Troponin T i5 nanograms/deciliter (ng/dl) and 0,3 micrograms/deciliter (mgd/l) for Crea. The established cut-off value for CK is 190 U/l, for Troponin T is 50 ng/dl and 1,2 mg/dl for Crea.

2.6. Data analysis {#sec0008}
------------------

Data were expressed as mean ± standard error of mean or as median with first and third quartiles. For comparing quantitative variables, the Student\'s t-test or the non-parametric Mann--Whitney U or Wilcoxon signed-rank test were used as appropriate. Normality of distribution was determined by Kolmogorov-Smirnov test. The correlation analysis was estimated using the Spearman\'s p coefficient A *p*-value \<0.05 was considered as statistically significant. All statistical analyses were performed using SPSS Statistics v.22 (IBM, Chicago, IL) and GraphPad PRISM 5 (La Jolla, CA).

2.7. Ethical consideration {#sec0009}
--------------------------

The study protocol was approved by the institutional ethics commission with an amendment to AN2017-0016 369/4.21 and informed consent was obtained, if applicable, from each patient included in the study. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki (6^th^ revision, 2008) as reflected in a priori approval by institutional ethics commission.

3. Results {#sec0010}
==========

3.1. Clinical characteristics of hospitalized COVID-19 patients {#sec0011}
---------------------------------------------------------------

The mean age of patients included into our study was 60.69 years with 37.5% (*n*=36) females. Patients characteristics are listed in [Table 1](#tbl0001){ref-type="table"} . Most COVID-19 patients reported fever (75.8%), cough (88.9%), muscle pain (66.7%) and fatigue (67.8%), whereas dyspnea was noted in 50% of patients. Gastrointestinal symptoms like nausea, vomiting, and diarrhea were present in 15.6%, 7.8% and 17.8%, respectively. Importantly, 61.8% of patients showed typical radiologic findings in imaging studies (chest X-ray or computed tomography). Most patients reported chronic diseases like hypertension (50.5%), type 2 diabetes (19.8%), pulmonary disease (11%) and 13.4% reported a history of smoking. During hospitalization (i.e. after liver enzyme testing) 66.3% of patients received antibiotic-therapy with cephalosporines in all cases to cover secondary infections, and 42.7% of patients received anti-viral therapy with favipiravir. Important to note, only 3 patients received antibiotic therapy and none received anti-viral therapy ahead of admission. On admission day, 32 non-ICU patients (39.5%) displayed elevated AST, 60% of patients at the ICU showed elevated AST, and no patient showed clinical or biochemical features of fulminant hepatitis ([Table 1](#tbl0001){ref-type="table"}). Skeletal muscle, myocardium, and kidney might all be sources of AST, therefore AST levels were correlated with CK (non significant (ns), data not shown), Troponin T (ns, data not shown) and Crea (ns, data not shown). ALT was elevated in only 5 patients on admission day. These findings are going in line with other studies, suggesting ALT elevation appears at a later timepoint during COVID-19 [@bib0021],[@bib0022],[@bib0026]. None of the patients showed elevated Bili, GGT and AP at a such early stage of disease. ICU patients displayed higher frequencies of fever (*p*=0.033), dyspnea (*p*=0.014) and imaging findings (*p*=0.012) at admission, compared to non ICU patients ([Table 1](#tbl0001){ref-type="table"}). During hospitalization none of the non ICU-patients was transferred to the ICU. The length of hospital stay was significantly longer in ICU patients (*p*\<0.001) and mortality rate was significantly higher in ICU patients (*p*\<0.001) ([Table 1](#tbl0001){ref-type="table"}). Patients admitted to the ICU showed significantly higher levels of AST (*p*=0.02), CRP (*p*\<0.001), LDH (*p*\<0.001), procalcitonin (PTC, *p*\<0.001), ferritin (*p*\<0.001) and IL-6 (*p*=0.003) ([Table 2](#tbl0002){ref-type="table"} ). Furthermore maximum AST (*p*\<0.001) and ALT (*p*\<0.001) during hospital stay were significantly higher and peaked significantly later during disease course (*p*\<0.001) in ICU patients ([Table 2](#tbl0002){ref-type="table"}).Table 1Patient characteristics in Covid-19 patients admitted to general ward (non ICU) or ICU.Table 1OverallNon ICUICUnon ICU vs ICU*nNn*pAge \[years\]60.69 ± 18.9159660.98 ± 20.128159.13 ± 10.5415nsFemales (%)36 (37.5)9632 (39.5)814 (26.7)15nsSmoker (%)11 (13.4)899 (11.8)762 (15.4)13nsAllergies (%)21 (23.3)9117 (22.1)774 (30.8)13nsMalignant disease (%)9 (9.9)919 (11.5)780 (0)13nsHypertension (%)46 (50.5)9138 (48.7)788 (61.5)13nsDiabetes (%)18 (19.8)9115 (19.2)783 (23.1)13nsChronic liver disease[\*]{.ul}^,^[\*\*]{.ul} (%)8 (8.8)915 (6.4)783 (23.1)13nsHeart disease (%)20 (122.2)9018 (23.4)772 (15.3)13nsPulmonary disease (%)10 (11)917 (9)783 (12.1)13nsImmunosuppression (%)3 (3.3)901 (1.3)772 (15.4)13nsFever \>37,3°C (%)69 (75.8)9156 (71.8)7813 (100)13**0.033**Dyspnea (%)45 (50)9034 (44.2)7711 (84.6)13**0.014**Cough (%)80 (88.9)9068 (88.3)7712 (92.3)13nsSputum (%)24 (26.7)9022 (28.6)772 (13.3)13nsHemoptysis (%)5 (5.6)895 (6.5)770 (0)13nsSore throat (%)26 (28.9)9023 (29.9)773 (23.1)13nsNasal obstruction (%)18 (20)9015 (19.5)773 (23.1)13nsMuscle ache (%)60 (66.7)9050 (64.9)7710 (76.9)13nsFatigue (%)61 (67.8)9051 (66.2)7710 (76.9)13nsNausea (%)14 (15.6)9013 (16.9)771 (7.7)13nsVomiting (%)7 (7.8)907 (9.1)770 (0)13nsDiarrhea (%)16 (17.8)9014 (18.2)772 (15.4)13nsImaging finding (%)55 (61.8)8943 (56.6)7612 (92.3)13**0.012**Antibiotic therapy on admisson day (%)14 (15.7)8911 (14.5)763 (23.1)13nsAntiviral therapy on admisson day (%)1 (1.2)861 (1.4)730 (0)13nsAntibiotic therapy during hospital stay (%)59 (66.3)8946 (60.5)7613 (100)13**0.04**Antiviral therapy during hospital stay (%)30 (34.5)8717 (23)7413 (100)13**\<0.001**Elevated AST41 (42.7)9632 (39.5)819 (60)15nsHospital stay (days)19.4 ± 7.2968.7 ± 6.38136.2 ± 15.715**\<0.001**ICU stay (days)24 ± 13.29608124 ± 13.215**\<0.001**Mortality7 (7.3)965 (6.2)812 (15.4)15**0.04**[^2][^3]Table 2Laboratory parameters in Covid-19 patients admitted to general ward (non ICU) or ICU.Table 2Non ICUICU*nNp*Bilirubin \[mg/dl\]0.45 (0.3-0.67)810.641 ± 0.3015nsAST \[U/l\]34 (23-56.5)8154.73 ± 18.40150.02ALT \[U/l\]25 (17-42)8144.93 ± 24.8315nsMaximum AST \[U/l\]57.4 ± 44.881179.9 ± 121.115\<0.001Maximum ALT \[U/l\]59.1 ± 32.981178.3 ± 116.915\<0.001Maximum AST after hospital admission (days)3.1 ± 2.08111.7 ± 5.615\<0.001Maximum ALT after hospital admission (days)3.9 ± 2.18115.5 ± 6.915**\<0.001**Liver stiffness (kPa)4.8 ± 2.725015--CK \[U/l\]111.3 ± 81.581107.6 ± 52.115nsTroponin T \[U/l\]16.8 ± 9.28110.9 ± 6.215nsCreatinine \[mg/dl\]0.85 ± 0.28810.84 ± 0.2115nsLDH \[U/l\]256.6 ± 95.981439.2 ± 176.215\<0.001GGT \[U/l\]38 (25-67)8147 (27-82)15nsAP \[U/l\]61 (47-72.5)8160 (50-69)15nsCRP \[mg/dl\]3.28 (0.58-7.35)8112.982 ± 9.3315\<0.001PCT \[µg/l\]0.08 (0.6-0.23)810.28 (0.2-0.7)15\<0.001IL-6 \[ng/l\]18.6 (5.3-68.3)8192.2 (18-171.6)150.003Leukocytes \[10^9^/l\]5.821 ± 1.94817.033 ± 3.2515nsHb \[g/l\]133.26 ± 17.3181131 ± 21.8615nsPlatelets \[10^9^/l\]220 (171-294.5)81227.67 ± 92.7715nsProthrombin time \[%\]1 (0.9-1)811.02 ± 0.1115nsFerritin \[µg/l\]525 (217-982)811650.67 ± 1187.1215\<0.001[^4]

3.2. Liver damage correlates with IL-6 and acute phase proteins {#sec0012}
---------------------------------------------------------------

IL-6 positively correlated with AST in all patients (*r* ^2^=0.481, *p*\<0.001, [Fig. 1](#fig0001){ref-type="fig"} A). In both ICU and non-ICU patients a positive correlation could be observed ([Fig. 1](#fig0001){ref-type="fig"}B) with more pronounced effects in ICU patients (*r* ^2^=0.610, *p*=0.016). Splitting our cohort in individuals with increased (≥ 50 U/l) and normal (\<50 U/l) AST concentration, we could observe higher IL-6 levels in non ICU patients (*p*\<0.001, [Fig. 1](#fig0001){ref-type="fig"}C) as well as ICU patients (*p*=0.048, [Fig. 1](#fig0001){ref-type="fig"}D) with elevated AST. IL-6 didn´t correlate with ALT, GGT, Bilirubin and AP on admission day.Fig. 1IL-6 correlates with AST and is increased in patients with impaired liver function. (A) IL-6 and AST levels correlate in all hospitalized patients. (B) IL-6 levels correlate with AST concentration in non ICU and ICU patients. Displayed are IL-6 concentrations in patients with normal AST and elevated AST in (C) non ICU and (D) ICU patients. Data are shown as mean ± SEM, *n*: (C-D). \**p*\<0.05; \*\**p*\<0.01; \*\*\**p*\<0.001 according to Spearman correlation or Student\'s *t*-test. AST, aspartate aminotransferase; ICU, intensive care unit; IL-6, interleukin 6.Fig 1

Likewise, CRP correlated with AST in all hospitalized patients (r^2^=0.38, *p*\<0.001, [Fig. 2](#fig0002){ref-type="fig"} A). Both ICU (*r* ^2^=0.539, *p*=0.038, [Fig. 2](#fig0002){ref-type="fig"}B) and non ICU (*r* ^2^=0.328, *p*=0.003, [Fig. 2](#fig0002){ref-type="fig"}B) patients displayed a correlation with CRP and AST at admission. In individuals with liver damage, CRP levels were higher in non-ICU patients (*p*\<0.001, [Fig. 2](#fig0002){ref-type="fig"}C), whereas we could not observe any significant difference in patients at the ICU (*p*=0.256, [Fig. 2](#fig0002){ref-type="fig"}D). Similarly, ferritin concentration correlated with AST (*r* ^2^=0.6, *p*\<0.001, [Fig. 3](#fig0003){ref-type="fig"} A), although in ICU patients this effect was more distinct (*r* ^2^=0.84, *p*\<0.001, [Fig. 3](#fig0003){ref-type="fig"}B) compared to non-ICU patients (*r* ^2^=0.578, *p*\<0.001, [Fig. 3](#fig0003){ref-type="fig"}B). In both non-ICU and ICU patients, individuals with elevated AST seem to have higher concentrations of ferritin ([Fig. 3](#fig0003){ref-type="fig"}C and D). Furthermore, LDH concentration correlated with AST (*r* ^2^=0.6, *p*\<0.001, [Fig. 4](#fig0004){ref-type="fig"} A), although in ICU patients this effect was more distinct (*r* ^2^=0.84, *p*\<0.001, [Fig. 4](#fig0004){ref-type="fig"}B) compared to non-ICU patients (*r* ^2^=0.578, *p*\<0.001, [Fig. 4](#fig0004){ref-type="fig"}B). In Non-ICU patients LDH levels were higher in individuals with increased AST (*p*\<0.01, [Fig. 4](#fig0004){ref-type="fig"}C), whereas ICU patients with altered AST only tended to be higher (*p*=0.162, [Fig. 4](#fig0004){ref-type="fig"}D). Furthermore, maximum AST and ALT levels correlated directly with IL-6, Ferritin and CRP in non-ICU patients ([Fig. 4](#fig0004){ref-type="fig"}E). Furthermore, we performed a longitudinal comparison of AST, ALT and Bilirubin. Liver parameters were more pronounced in patients with higher IL-6 levels. Data are now presented in Supplementary Fig. 1. We compared outcome data with IL-6 and acute phase protein levels. IL-6 was positively correlated with duration of hospital stay (*r* ^2^=0.109, *p*≤0.01 Supp. Fig. 2A), ICU stay (*r* ^2^=0.162, *p*≤0.001 Supp. Fig. 2A), days of mechanical ventilation (*r* ^2^=0.146, *p*≤0.001 Supp. Fig. 2A), and negatively correlated with mean arterial pressure (*r* ^2^=0.082, *p*≤0.01 Supp. Fig. 2A). CRP also showed a significant correlation whereas LDH, showed no significant correlation with mean arterial pressure. Supp. Fig. 2b and c). Ferritin was not significantly correlated to patient´s outcome (data not shown).Fig. 2CRP correlates with AST and is increased in patients with impaired liver function. (A) CRP and AST levels correlate in all hospitalized patients. (B) CRP levels correlate with AST concentration in non ICU and ICU patients. Displayed are CRP concentrations in patients with normal AST and elevated AST in (C) non ICU and (D) ICU patients. Data are shown as mean ± SEM, *n*: (C-D). \**p*\<0.05; \*\**p*\<0.01; \*\*\**p*\<0.001 according to Spearman correlation or Student\'s *t*-test. AST, aspartate aminotransferase; CRP, C-reactive protein; ICU, intensive care unit.Fig 2Fig. 3Ferritin correlates with AST and is increased in patients with impaired liver function. (A) Ferritin and AST levels correlate in all hospitalized patients. (B) Ferritin levels correlate with AST concentration in non ICU and ICU patients. Displayed are ferritin concentrations in patients with normal AST and elevated AST in (C) non ICU and (D) ICU patients. Data are shown as mean ± SEM, *n*: (C-D). \**p*\<0.05; \*\**p*\<0.01; \*\*\**p*\<0.001 according to Spearman correlation or Student\'s *t*-test. AST, aspartate aminotransferase; ICU, intensive care unit.Fig 3Fig. 4LDH correlates with AST and is increased in patients with impaired liver function. (A) LDH and AST levels correlate in all hospitalized patients. (B) LDH levels correlate with AST concentration in non ICU and ICU patients. Displayed are LDH concentrations in patients with normal AST and elevated AST in (C) non ICU and (D) ICU patients. (E) Correlation heat map of biochemical parameters in all hospitalized patients. Tile colours code for magnitude of the correlation with darker shades indicating stronger correlation. The first two decimal digits of r are displayed. Only significant correlations are shown. Data are shown as mean ± SEM, *n*: (C-D). \**p*\<0.05; \*\**p*\<0.01; \*\*\**p*\<0.001 according to Spearman correlation or Student\'s *t*-test. LDH, lactate dehydrogenase; AST, aspartate aminotransferase; ICU, intensive care unit.Fig 4

4. Discussion {#sec0013}
=============

Previous studies reported signs of liver injury by biochemical and histologic means in COVID-19 patients [@bib0004],[@bib0019],[@bib0021], [@bib0022], [@bib0023]\]. However, the origin of hepatic damage in COVID-19 is poorly understood and potentially involves systemic inflammation, viral replication or drug-induced liver injury. Today, we lack evidence for SARS-CoV-2 replication in the liver and our study renders drug-induced liver injury as cause of elevated liver enzymes very unlikely. We rather found a direct correlation between systemic inflammation (indicated by IL-6, CRP and ferritin) and liver [damage]{.ul}. IL-6 production may stem from immune cells [@bib0032] fibroblasts, endothelial cells [@bib0033] and hepatocytes [@bib0027],[@bib0034] which orchestrates an hepatic acute phase response [@bib0032],[@bib0035],[@bib0036]. While IL-6 signaling impinges on hepatic regeneration [@bib0027], clinical studies (that for example tested the effect of IL-6 administration in cancer patients) demonstrated a critical role of this pathway in hepatic injury and hepatotoxicity [@bib0037], [@bib0038], [@bib0039]. In line with a critical impact of systemic inflammation and specifically IL-6 on liver injury, we noted a direct correlation between acute phase proteins and IL-6 in the serum of COVID-19 patients with elevated AST. Based on previous reports and our study, with the limitation of the Cross-sectional design, we propose that the systemic inflammatory response to SARS-CoV-2 infection to COVID-19 patients serves as a fuel of hepatic injury. In line with this, our findings appeared more pronounced in COVID-19 patients with a more severe CRS (i.e. that required intensive care measures). Vice versa, tocilizumab, a recombinant humanized monoclonal antibody targeting the human IL-6 receptor, reversed liver injury during CRS that was induced by non-infectious means (i.e. CAR-T cell therapy) [@bib0040],[@bib0041].

While experimental evidence suggests that blockade of an inflammatory response in SARS-CoV-2-related CRS improves the course of infection [@bib0042],[@bib0043], clinical trials are pending. In the previous MERS-CoV epidemic, IL-6 and other inflammatory cytokines, such as IL-2 have been identified as key players during infection and trigger hepatic injury [@bib0044],[@bib0045]. In COVID-19 patients, elevated IL-6 concentrations (amongst others) have been described [@bib0046] and a cytokine signature was indeed associated with loss of lung function, lung injury and outcome [@bib0047]. As such, it appears that SARS-CoV-2 potently triggers a systemic cytokine response that is detrimental for some patients (as in CRS) while factors that control this response remain undetermined. This cytokine response, but probably not viral burden, seems to play the key role in disease severity and patient outcome [@bib0048].

Conflict of interest {#sec0014}
====================

All authors declare no conflict of interest.

Funding {#sec0015}
=======

This study is supported by the excellence initiative VASCage (Centre for Promoting Vascular Health in the Ageing Community), an R&D K-Centre (COMET program - Competence Centers for Excellent Technologies) funded by the Austrian Ministry for Transport, Innovation and Technology, the Austrian Ministry for Digital and Economic Affairs and the federal states Tyrol, Salzburg and Vienna.

Appendix. Supplementary materials {#sec0017}
=================================

Image, application 1

No funders were involved in the study concept, design, conduct, data analyses, writing of this manuscript, or in the decision to submit this work for publication.

Supplementary material associated with this article can be found, in the online version, at doi:[10.1016/j.dld.2020.08.004](https://doi.org/10.1016/j.dld.2020.08.004){#interref0001}.

[^1]: These authors contributed equally to this work.

[^2]: \*\*MAFLD (*n*=6) \*\*chronic hepatitis B infection (*n*=2).

[^3]: Patient characteristics in Covid-19 patients admitted to general ward (non ICU) or ICU. Data are expressed as case numbers (percentage) or mean ± standard deviation. AST, aspartate aminotransferase; ICU, intensive care unit; MAFLD, metabolic associated fatty liver disease.

[^4]: Laboratory parameters of Covid-19 patients admitted to ICU or general ward (non ICU). Quantitative data were expressed as means ± standard deviation if normally distributed. For non-normally distributed variables, data are shown as medians with first and third quartiles. AP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; kPa, Kilopascal; CK, creatinine kinase; CRP, C-reactive protein; GGT, gamma-glutamyl transferase; Hb, hemoglobin; ICU, intensive care unit; IL-6, interleukin 6; LDH, lactate dehydrogenase; mg/dl, milligrams/deciliter; µg/l, micrograms/liter; PCT, procalcitonin; U/l, Units/liter.
